Valneva SE
For the period ended Dec 31, 2025. Filed Dec 31, 2025.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Dec 31, 2025 · Filed Dec 31, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
Saint-Herblain (France), Pune, (India), December 31, 2025 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company today announced that they have mutually agreed to discontinue their license agreement for Valneva’s single-shot chikungunya vaccine.
Valneva´s strategic intent in regaining full rights is to assume direct control over its supply chain and commercialization for endemic high-risk countries, thereby accelerating access for regions most affected by the disease.
Supporting access to the vaccine in low-and-middle-income countries (LMICs) falls within the framework of the funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 2024 with co-funding from the European Union 1.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.